Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Unmesh, Gopalakrishnan"'
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cornelius F. Waller, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Eduardo Yanez Ruiz, Ihor Vynnychenko, Unmesh Gopalakrishnan, Abhijit Barve, Jay Herson, Ashwani Marwah, Virote Sriuranpong, Sirshendu Roy, Hope S. Rugo, Alexey Manikhas, Miguel Hernandez-Bronchud, Subramanian Loganathan, Hans Friedrich Koch, Joseph D. Parra, Sarika Deodhar, Igor Bondarenko, Eduardo J. Pennella
Publikováno v:
Breast, Vol 58, Iss, Pp 18-26 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d8b0495b77dd28c7ee458c4ff26623
http://www.sciencedirect.com/science/article/pii/S0960977621003489
http://www.sciencedirect.com/science/article/pii/S0960977621003489
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96d7db24623d3a61483158ddd9eb8f3
https://doi.org/10.1007/s10549-021-06197-5
https://doi.org/10.1007/s10549-021-06197-5
Autor:
Cornelius F. Waller, Aleksei Manikhas, Eduardo J. Pennella, Igor Bondarenko, Guzel Mukhametshina, Maria Luisa Abesanis Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Ray, Miguel Hernandez-Bronchud, Jay Herson, Joseph D. Parra, Gia Nemsadze, Unmesh Gopalakrishnan, Subramanian Loganathan, Rafael Muniz, Abhijit Barve, Hope S. Rugo
Publikováno v:
Journal of Clinical Oncology. 37:1021-1021
1021 Background: The multicenter, double-blind, randomized, parallel-group, phase 3 Heritage trial (NCT02472964) evaluated efficacy and safety of trastuzumab-dkst (Ogivri), a trastuzumab biosimilar, vs trastuzumab, plus taxane as first-line therapy f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63039a9ce89216fb07c4644a33551536
https://doi.org/10.1200/jco.2019.37.15_suppl.1021
https://doi.org/10.1200/jco.2019.37.15_suppl.1021